home / stock / evlo / evlo news

EVLO News and Press, Evelo Biosciences Inc. From 10/28/21

Stock Information
Company Name: Evelo Biosciences Inc.
Stock Symbol: EVLO
Market: OTC
Website: evelobio.com
Menu
EVLO EVLO Quote EVLO Short EVLO News EVLO Articles EVLO Message Board
Get EVLO Alerts

News, Short Squeeze, Breakout and More Instantly...
EVLO - Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q3 2021 Results - Earnings Call Transcript

Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Conference Call October 28, 2021 8:30 AM ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Mark Plinio - Chief Commercial Officer Jonathan Zung - Chief Development Officer Conference Call Participan...
EVLO - Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights

–Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies– –Dosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to begin during 4Q 2021– –Preclinical data support development of EDP1867 in neuroinflammator...

EVLO - Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference cal...

EVLO - Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change PR Newswire CAMBRIDGE, Mass. , Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the p...
EVLO - Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of multiple sclerosis– –Data support development of EDP186...

EVLO - Protagonist Therapeutics, Adamas Pharmaceuticals leads healthcare gainers; Voyager Therapeutics, Protalix BioTherapeutics among major losers

Gainers: Protagonist Therapeutics (NASDAQ:PTGX) +82%, Adamas Pharmaceuticals (NASDAQ:ADMS) +74%, Flexion Therapeutics (NASDAQ:FLXN) +62%, Evelo Biosciences (NASDAQ:EVLO) +16%, Progenity (NASDAQ:PROG) +16%. Losers: Voyager Therapeutics (NASDAQ:VYGR)...

EVLO - Sonoma Pharmaceuticals, Evelo Biosciences leads healthcare gainers; Altimmune, InMode among major losers

Gainers: Sonoma Pharmaceuticals (NASDAQ:SNOA) +33%, Evelo Biosciences (NASDAQ:EVLO) +12%, ZIVO Bioscience (NASDAQ:ZIVO) +12%, Viridian Therapeutics (NASDAQ:VRDN) +7%, Harpoon Therapeutics (NASDAQ:HARP) +7%. Losers: Altimmune (NASDAQ:ALT) -20%, ...
EVLO - Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX(TM), to Treat Systemic Inflammatory Disease

–Clinically and statistically significant improvement in PASI-50 score achieved– –EDP1815 safety and tolerability data comparable to placebo in study– –EDP1815 advancing towards registration studies in psoriasis– –Management to host con...

EVLO - Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will host a fireside chat at the Cantor Global Healthcare Conference on Monda...

EVLO - SYRS, BGRY and OPAD among mid-day movers

Gainers: Helbiz HLBZ +135%. Corvus Pharmaceuticals CRVS +77%. Innate Pharma IPHA +37%. Worksport (OTCQB:WKSP) +20%. Priority Technology Holdings (NASDAQ:PRTH) +15%. Entasis Therapeutics (NASDAQ:ETTX) +15%. Capital Senior Living Corporation (NYSE:CSU) +13%. Evelo (NASDAQ:EVLO) +...
Previous 10 Next 10